Lexicon Pharmaceuticals Inc
$ 1.89
0.53%
11 Jun - close price
- Market Cap 839,531,000 USD
- Current Price $ 1.89
- High / Low $ 1.94 / 1.84
- Stock P/E N/A
- Book Value 0.48
- EPS -0.07
- Next Earning Report 2026-08-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.05 %
- ROE -0.16 %
- 52 Week High 2.53
- 52 Week Low 0.64
About
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development and commercialization of pharmaceutical products. The company is headquartered in The Woodlands, Texas.
Analyst Target Price
$3.77
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-07 | 2026-03-05 | 2025-11-06 | 2025-08-06 | 2025-05-13 | 2025-03-06 | 2024-11-12 | 2024-08-01 | 2024-05-02 | 2024-03-11 | 2023-11-08 | 2023-08-03 |
| Reported EPS | -0.0026 | -0.04 | -0.04 | 0.01 | -0.07 | -0.09 | -0.18 | -0.17 | -0.2 | -0.2 | -0.21 | -0.22 |
| Estimated EPS | -0.04 | -0.067 | -0.07 | -0.08 | -0.1 | -0.1248 | -0.17 | -0.19 | -0.2 | -0.23 | -0.22 | -0.16 |
| Surprise | 0.0374 | 0.027 | 0.03 | 0.09 | 0.03 | 0.0348 | -0.01 | 0.02 | 0 | 0.03 | 0.01 | -0.06 |
| Surprise Percentage | 93.5% | 40.2985% | 42.8571% | 112.5% | 30% | 27.8846% | -5.8824% | 10.5263% | 0% | 13.0435% | 4.5455% | -37.5% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-05 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.05 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: LXRX
2026-06-11 15:10:18
This article compares Lexicon Pharmaceuticals (LXRX) and Pfizer (PFE), highlighting the contrast between a small, growing biotech firm and a large, established pharmaceutical giant. It delves into their recent financial performances, noting Lexicon's significant revenue growth but net loss, and Pfizer's substantial revenue and net income despite a slight revenue dip. The analysis also covers their respective risk profiles, including regulatory challenges and accumulated deficits for Lexicon, and Pfizer's broad market presence.
2026-06-05 17:39:57
Lexicon Pharmaceuticals director Ivan Cheung converted 89,312 restricted stock units (RSUs) into common shares on June 3, 2026, at a price of $0.00 per share. Following this non-cash equity award event, Cheung directly holds 89,312 common shares, with no remaining restricted stock units from this grant. Each RSU represented a contingent right to receive one common share, fully vesting on the first anniversary of the grant date.
2026-06-05 04:08:54
Lexicon Pharmaceuticals director Sam L. Barker converted 89,312 restricted stock units (RSUs) into common shares on June 3, 2026, receiving 89,312 shares at $0.00 per share. This transaction was an equity compensation event, not an open-market trade. Following the conversion, Barker directly owns 213,771 shares of Lexicon Pharmaceuticals common stock.
2026-06-04 20:39:14
LEXICON PHARMACEUTICALS, INC. director Christopher J. Sobecki exercised 89,312 restricted stock units, converting them into an equivalent number of common shares. Following this transaction, his direct holdings in the company amount to 293,177 shares of common stock. The transaction, considered neutral in its impact and sentiment, involved no monetary cost per share for the conversion.
2026-06-04 20:39:14
Lexicon Pharmaceuticals director Diane E. Sullivan converted 89,312 restricted stock units (RSUs) into common shares on June 3, 2026. This transaction was compensation-related, with a stated price of $0.00 per share, and increased her direct ownership to 126,122 shares of common stock. The RSUs vested fully on the first anniversary of their grant date.
2026-06-04 20:39:14
Lexicon Pharmaceuticals (NASDAQ: LXRX) director Raymond Debbane converted 89,312 restricted stock units (RSUs) into common stock at an exercise price of $0.00 per unit, directly increasing his holdings to 1,995,498 shares. Entities associated with him also hold significant indirect positions in the company. This transaction, filed on a Form 4, indicates an exercise of equity compensation rather than a sale of stock.
